In the Russian Federation, Bragina et al. were the first to implement aclinical trial utilizing the radiopharmaceutical[99mTc]Tc-ZHER2:41071 [78]for the targeted radionuclide diagnostics of HER2-positive breast cancer, usingaffibody molecules. This evidence concerns the gene ERBB2 and breast cancer.